Cargando…

Enfuvirtide−PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties

Enfuvirtide (ENF) is a clinically used peptide drug for the treatment of HIV infections, but its poor pharmacokinetic profile (T(1/2) = 1.5 h in rats) and low aqueous solubility make the therapy expensive and inconvenience. In this study, we present a simple and practical strategy to address these p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Shuihong, Wang, Yan, Zhang, Zhenxing, Lv, Xun, Gao, George F., Shao, Yiming, Ma, Liying, Li, Xuebing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Masson SAS. 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115413/ https://www.ncbi.nlm.nih.gov/pubmed/27240277 http://dx.doi.org/10.1016/j.ejmech.2016.05.027

Ejemplares similares

Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide
por: Dingens, Adam S., et al.
Publicado: (2019)

HIV-1 Fusion Inhibitor Peptides Enfuvirtide and T-1249 Interact with Erythrocyte and Lymphocyte Membranes
por: Matos, Pedro M., et al.
Publicado: (2010)

Sphingopeptides: dihydrosphingosine‐based fusion inhibitors against wild‐type and enfuvirtide‐resistant HIV‐1
por: Ashkenazi, Avraham, et al.
Publicado: (2012)

Enfuvirtide biosynthesis in thermostable chaperone-based fusion
por: Zenin, Vladimir, et al.
Publicado: (2022)

Enfuvirtide antiretroviral therapy in HIV-1 infection
por: Kitchen, Christina MR, et al.
Publicado: (2008)

Enfuvirtide in therapy at patients with HIV-infection and tuberculosis
por: Kravchenko, AV, et al.
Publicado: (2010)

Fusion inhibitors and their evolving role during salvage antiretroviral therapy. Seven years of experience with enfuvirtide
por: Manfredi, Roberto
Publicado: (2010)

Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy
por: Zhu, Xiaojie, et al.
Publicado: (2015)

Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action
por: Wang, Chen, et al.
Publicado: (2019)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Impact of the HIV-1 env Genetic Context outside HR1–HR2 on Resistance to the Fusion Inhibitor Enfuvirtide and Viral Infectivity in Clinical Isolates
por: Baatz, Franky, et al.
Publicado: (2011)

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor
por: Hu, Yue, et al.
Publicado: (2022)

Characterization of Gp41 Polymorphisms in the Fusion Peptide Domain and T-20 (Enfuvirtide) Resistance-Associated Regions in Korean HIV-1 Isolates
por: Jang, Dai-Ho, et al.
Publicado: (2014)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico
por: Huerta-García, Gloria, et al.
Publicado: (2014)

Short-course intensification with enfuvirtide in virologic failure: impact on intracellular HIV reservoir and on viral tropism (INNOVE study)
por: Ghosn, J, et al.
Publicado: (2010)

Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability
por: Smith, Michele, et al.
Publicado: (2018)

A Blast From the Past: Abdominal Wall Amyloidosis Due to Enfuvirtide Injections
por: Costiniuk, Cecilia, et al.
Publicado: (2023)

Stabilization of Resveratrol in Blood Circulation by Conjugation to mPEG and mPEG-PLA Polymers: Investigation of Conjugate Linker and Polymer Composition on Stability, Metabolism, Antioxidant Activity and Pharmacokinetic Profile
por: Siddalingappa, Basavaraj, et al.
Publicado: (2015)

A Novel Class of Anti-HIV Agents with Multiple Copies of Enfuvirtide Enhances Inhibition of Viral Replication and Cellular Transmission In Vitro
por: Chang, Chien-Hsing, et al.
Publicado: (2012)

A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies
por: Xu, Ling, et al.
Publicado: (2023)

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG(4)-Chol
por: Quinn, Killian, et al.
Publicado: (2017)

Thermostable chaperone-based polypeptide biosynthesis: Enfuvirtide model product quality and protocol-related impurities
por: Zenin, Vladimir, et al.
Publicado: (2023)

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19
por: He, Lin, et al.
Publicado: (2023)

PEG Conjugated Zein Nanoparticles for In Vivo Use
por: van Ballegooie, Courtney, et al.
Publicado: (2022)

Structure-based design of 5′-substituted 1,2,3-triazolylated oseltamivir derivatives as potent influenza neuraminidase inhibitors
por: Wang, Pengfei, et al.
Publicado: (2021)

Synthesis, physicochemical characterization, toxicity and efficacy of a PEG conjugate and a hybrid PEG conjugate nanoparticle formulation of the antibiotic moxifloxacin
por: Tshweu, Lesego L., et al.
Publicado: (2020)

Characterization of Potent Fusion Inhibitors of Influenza Virus
por: Rowse, Michael, et al.
Publicado: (2015)

Synthesis of Acid-Labile PEG and PEG-Doxorubicin-Conjugate Nanoparticles via Brush-First ROMP
por: Gao, Angela X., et al.
Publicado: (2014)

Sargassum fusiforme fraction is a potent and specific inhibitor of HIV-1 fusion and reverse transcriptase
por: Paskaleva, Elena E, et al.
Publicado: (2008)

Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection
por: Lan, Qiaoshuai, et al.
Publicado: (2021)

T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy
por: Bucciardini, R, et al.
Publicado: (2008)

Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients
por: Zhang, Hongwei, et al.
Publicado: (2016)

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers
por: Barroso, Sergio, et al.
Publicado: (2019)

Development of a HPLC fluorometric method for the quantification of enfuvirtide following in vitro releasing studies on thermosensitive in situ forming gel
por: Li, Huanhuan, et al.
Publicado: (2023)

Spinal cord fusion with PEG-GNRs (TexasPEG): Neurophysiological recovery in 24 hours in rats
por: Kim, C-Yoon, et al.
Publicado: (2016)

A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile
por: Xu, Wei, et al.
Publicado: (2022)

667. Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938, a Novel and Potent NonFusion Replication Inhibitor of Respiratory Syncytial Virus
por: Jiang, Li-Juan, et al.
Publicado: (2019)

PEG–Ursolic Acid Conjugate: Synthesis and In Vitro Release Studies
por: Zacchigna, Marina, et al.
Publicado: (2014)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7nkt0chm2j2p1j81sccdmt7gr1